Dynavax pays Vaxart $30M for oral COVID-19 vaccine program
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine, positioning the biotech to see phase 2b data before placing a bigger bet on the…
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine, positioning the biotech to see phase 2b data before placing a bigger bet on the…